Indaptus Therapeutics, Inc.
Clinical trials sponsored by Indaptus Therapeutics, Inc., explained in plain language.
Biopharmaceutical company developing immunotherapies for cancer and viral infections.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer cocktail aims to rev up immune system against tumors Results expected Jun 2027 (estimated)